2015
DOI: 10.1172/jci81229
|View full text |Cite
|
Sign up to set email alerts
|

Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
209
1
5

Year Published

2015
2015
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 243 publications
(221 citation statements)
references
References 70 publications
6
209
1
5
Order By: Relevance
“…Partial or complete T-cell depletion and posttransplant cyclophosphamide may reduce the risks of acute and chronic graft-versus-host disease (GVHD). [195][196][197][198] The biggest challenge remains prevention of posttransplant relapse. 199 Preparative regimens including novel agents or radiolabeled monoclonal antibodies, 200 or therapy during the early posttransplant period with tyrosine kinase inhibitors or hypomethylating agents (HMAs) are being tested.…”
Section: Org Frommentioning
confidence: 99%
“…Partial or complete T-cell depletion and posttransplant cyclophosphamide may reduce the risks of acute and chronic graft-versus-host disease (GVHD). [195][196][197][198] The biggest challenge remains prevention of posttransplant relapse. 199 Preparative regimens including novel agents or radiolabeled monoclonal antibodies, 200 or therapy during the early posttransplant period with tyrosine kinase inhibitors or hypomethylating agents (HMAs) are being tested.…”
Section: Org Frommentioning
confidence: 99%
“…21,22 Because allogeneic mHAgs are not expressed by thymic antigen-presenting cells (APCs) of self-origin, alloreactive T cells specific for mHAgs occur almost exclusively in the naive T-cell repertoire. 16 Recent clinical protocols of selective depletion of naive T cells from the graft 23,24 therefore have the potential to profoundly ablate T-cell alloreactivity after HLA-matched sibling HCT. This approach is promising for nonmalignant disorders where GVL is not an issue, but must be carefully weighed against the disease risk for individual patients transplanted for malignant disease.…”
Section: Introductionmentioning
confidence: 99%
“…However, it must be noted that although the CMV-specific memory T cells within this polyclonal T-cell population effectively controlled CMV, the contaminating naive T cells were also capable of inducing GVHD. Thus, logical clinical approaches to treat CMV infection in patients with GVHD should focus on comparing the transfer of pathogen-specific memory T cells expanded by in vitro culture with appropriate antigen, vs the transfer of naive T-cell-depleted memory T cells, as recently described by Bleakley et al 42 The longevity of these adoptively transferred T cells is an important clinical consideration and future studies should address this issue. Most current clinical protocols focus on managing CMV disease with preemptive antiviral therapy administered at first evidence of active infection.…”
mentioning
confidence: 99%